These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 9143885)

  • 1. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z; Roggenkämper P
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr; 235(4):197-9. PubMed ID: 9143885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis.
    Simonetta Moreau M; Cauhepe C; Magues JP; Senard JM
    Br J Dermatol; 2003 Nov; 149(5):1041-5. PubMed ID: 14632812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Neurotox Res; 2009 Apr; 15(3):224-31. PubMed ID: 19384595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study.
    Marchetti A; Magar R; Findley L; Larsen JP; Pirtosek Z; Růzicka E; Jech R; Sławek J; Ahmed F
    Mov Disord; 2005 Aug; 20(8):937-44. PubMed ID: 15810022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Same-patient prospective comparison of Botox versus Dysport for the treatment of primary axillary hyperhidrosis and review of literature.
    Vergilis-Kalner IJ
    J Drugs Dermatol; 2011 Sep; 10(9):1013-5. PubMed ID: 22052270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®.
    Kollewe K; Mohammadi B; Köhler S; Pickenbrock H; Dengler R; Dressler D
    J Neural Transm (Vienna); 2015 Mar; 122(3):427-31. PubMed ID: 25059456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia: A Double-Blind, Randomized, Crossover Trial.
    Rystedt A; Zetterberg L; Burman J; Nyholm D; Johansson A
    Clin Neuropharmacol; 2015; 38(5):170-6. PubMed ID: 26366966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
    Sane S; Ali MJ; Naik MN
    Korean J Ophthalmol; 2019 Oct; 33(5):430-435. PubMed ID: 31612653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
    Badarny S; Ibrahim R; Susel Z; Zaina A; Nasar R; Badarny Y
    Medicine (Baltimore); 2021 Jun; 100(25):e26481. PubMed ID: 34160460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.
    Ranoux D; Gury C; Fondarai J; Mas JL; Zuber M
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):459-62. PubMed ID: 11909903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm.
    Yoon JS; Kim JC; Lee SY
    Korean J Ophthalmol; 2009 Sep; 23(3):137-41. PubMed ID: 19794937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.